Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARQ 501 · 6 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| ARQ 501 | DRUG | - |
Inclusion Criteria: 1. Able to provide signed and dated informed consent document prior to study-specific screening procedures. 2. Histologically or cytologically confirmed locally advanced, recurrent or metastatic SCCHN. 3. Measurable disease per RECIST. 4. ≥ 18 years old. 5. Karnofsky performance...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARQ 501 is an investigational small molecule being studied for the treatment of cancer, including head and neck neoplasms, advanced solid tumors, and carcinoma. It has been evaluated in clinical trials for these oncology indications, though it remains in clinical development and is not approved for any use.
ARQ 501 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is an oncology small molecule that has been studied in early-phase clinical trials for various cancer types.
ARQ 501 has been studied in Phase 1 and Phase 2 clinical trials. All three completed trials include two Phase 1 studies and one Phase 2 study. The drug is investigational and has not received FDA approval, as it is still in clinical development.
ARQ 501 has been studied in three completed clinical trials. NCT00075933 was a Phase 1 study in subjects with cancer enrolling 80 participants. NCT00310518 was a Phase 2 study in adult patients with leiomyosarcoma enrolling 30 participants. NCT00524524 was a Phase 1 exploratory biomarker study in patients with advanced solid tumors enrolling 9 participants.
ARQ 501 is the name used in clinical trials for this investigational oncology small molecule. No alternative names have been reported for this drug in the trial records, so it is not known to be the same as any other marketed or investigational agent.